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Adoptive T cell therapy (ACT) is a promising treatment
for melanoma patients with a clinical response rate of
about 50%. However, half of patients treated do not
respond to this therapy, underlining the need for
improvement . One of the limitations of ACT is the poor
effector function of transferred T cells influenced by the
immunosuppressive tumor microenvironment. In order
to identify pathways which may contribute to this obser-
vation, we used a murine ACT model in which mice
bearing established B16 tumors were treated with Pmel T
cells which recognize the melanoma antigen gp100 in the
context of H-2Db. Pmel T cells were recovered on day
6 and 13, after transfer, from the tumor and spleen of
treated mice and their gene expression patterns were
compared. We found that 720 genes were differentially
expressed by T cells recovered from the tumor site com-
pared to those recovered from the spleen. Amongst the
differentially expressed genes were several transcription
factors, including Runx2, Rora, E2F1 and Tcf7. After an
initial in vivo screen, Runx2 overexpressing Pmels con-
ferred a worse antitumor effect when compared to the
control Pmels (median tumor size 30.7 vs 20.7 mm2
respectively on day 7 after T cell transfer, p<0.05). We
also found fewer numbers of circulating Pmels in mice
that received Runx2 overexpressing Pmels when com-
pared to mice that received control Pmels. In addition,
there was decreased accumulation of Runx2 overexpres-
sing Pmels at the tumor site when compared to the con-
trol Pmel (Median luciferase output of 2.0X107 vs
9.0X107 photons/s/cm2/sr, respectively on day 6 after
T cell transfer, p value =0.042). To further interrogate
the role of Runx2 in T cells, we assessed the production
of IFN-g after stimulation in vitro with either plate
bound anti-CD3 or gp100 expressing tumor cells. We
found that IFN-g production was comparable between
Runx2 overexpressing Pmels and control Pmels after
anti-CD3 stimulation. However, IFN-g production was
impaired in Runx2 overexpressing Pmels upon stimula-
tion with tumor cells. Furthermore, in vitro characteriza-
tion also revealed that Runx2 overexpressing Pmels have
decreased proliferation and display an apoptotic pheno-
type. Taken together, our studies suggest that Runx2
regulates apoptosis, proliferation and IFN-g production
in tumor reactive T cells. Further studies to mechanisti-
cally understand these findings are ongoing.
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